Sino Biological, Inc., a biotechnology company listed on ChiNext (SZSE: 301047), provides biological research reagents and related technical contract research services, is pleased to announce its physical geographic expansion, adding a new location in Houston, Texas.
Novartis AG executes licence option with Molecular Partners
Latest NewsAfter Molecular Partners AG reported an 78% reduction of hospitalisation by a single ensovibep dose in infected COVID-19 patients, Novartis AG is to pay a CHF150m milestone.
Neurimmune inks US-$760 deal with AstraZeneca
Latest NewsNeurimmune has entered into a collaboration and license agreement with AstraZeneca subsidiary Alexion Pharmaceuticals to commercialise its antibody NI006.
Santhera finds Chinese marketing partner for vamorolone
Latest NewsSwiss Santhera Pharmaceuticals has entered into a $124m licence deal with Chinese Sperogenix Therapeuticis to market its DMD drug vamorolone.
DNA Script bags US$200m financing
Latest NewsModerna’s US-French partner DNA Script has raised additional $35m as a second tranche of a Series C financing to advance its Enzymatic DNA Synthesis platform, Syntax.
Sound Bioventures Fund I AB closes at €110m
Latest NewsNovo Holdings, together with Saminvest, Vækstfonden, the European Investment Fund and its three co-founders have put €110m in the first fund of Sound Bioventures AB.
Sino Biological Establishes New Location in Houston, Texas
Sponsored PublicationsSino Biological, Inc., a biotechnology company listed on ChiNext (SZSE: 301047), provides biological research reagents and related technical contract research services, is pleased to announce its physical geographic expansion, adding a new location in Houston, Texas.
Sino Biological Deposits Recombinant Omicron Proteins and Antibodies to BEI Resources
Sponsored PublicationsSino Biological, Inc. has recently deposited reagents for the Omicron variant, including recombinant proteins to Spike and Nucleocapsid, and antibody products to a central repository for reagents to support infectious disease research. With the addition of the Omicron products to previously deposited array of SARS-CoV-2 reagents, researchers can readily get access to them by registering with BEI Resources.
Omicron variant more harmless than Delta
Latest NewsThe new year begins with good news.
New tools to support AAV manufacturing
BackgroundWith the rapid developments in the field of gene therapy, the use of viral vectors, especially AAV, to treat various monogenic, inherited diseases in human patients is gaining momentum. Nonetheless, there are still options to optimise the production of such vectors in mammalian cells.
Merck aquired AmpTec to expand mRNA capabilities
BackgroundThis year, Merck KGaA Darmstadt, Germany has acquired AmpTec, an internationally active
contract manufacturing company (CMO) with comprehensive services for manufacturing of synthetic RNAs and mRNAs and more than 15 years of experience, with cGMP compliant manufacturing capabilities in development. This marks an exciting new chapter, where our combined expertise will allow us to offer our customers innovative technologies and products to help advance life-enhancing therapeutics.